Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal rituximab in secondary progressive multiple sclerosis
2012-004436-36Phase 2Terminated
- Sponsor
- University Hospital Odense
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in secondary-progressive multiple sclerosis (SPMS), sponsored by University Hospital Odense. Primary endpoint: Change in spinal fluid immune response after 1 and 3 months. Started Apr 2013; status: terminated.
02
Drugs
rituximab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2012-004436-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004436-36.